ATE113059T1 - Nukleosid-derivate. - Google Patents

Nukleosid-derivate.

Info

Publication number: ATE113059T1
Authority: AT; Austria
Prior art keywords: group; alkyl; unbranched; branched; formula
Prior art date: 1987-06-24

Application number

AT88905594T

Other languages

English (en)

Inventor

Jim Haralambidis

Original Assignee

Florey Howard Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-24

Filing date

1988-06-24

Publication date

1994-11-15

1988-06-24 Application filed by Florey Howard Inst filed Critical Florey Howard Inst

1994-11-15 Application granted granted Critical

1994-11-15 Publication of ATE113059T1 publication Critical patent/ATE113059T1/de

Links

150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 3
125000006239 protecting group Chemical group 0.000 abstract 3
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
239000003550 marker Substances 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
230000002285 radioactive effect Effects 0.000 abstract 2
229910019142 PO4 Inorganic materials 0.000 abstract 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
125000006245 phosphate protecting group Chemical group 0.000 abstract 1
SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
238000012163 sequencing technique Methods 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT88905594T 1987-06-24 1988-06-24 Nukleosid-derivate. ATE113059T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPI266687		1987-06-24

Publications (1)

Publication Number	Publication Date
ATE113059T1 true ATE113059T1 (de)	1994-11-15

Family

ID=3772261

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT88905594T ATE113059T1 (de)	1987-06-24	1988-06-24	Nukleosid-derivate.

Country Status (9)

Country	Link
US (1)	US5552540A (de)
EP (1)	EP0366685B1 (de)
JP (1)	JP2828642B2 (de)
AT (1)	ATE113059T1 (de)
AU (1)	AU598946B2 (de)
CA (1)	CA1340032C (de)
DE (1)	DE3851889T2 (de)
NZ (1)	NZ225176A (de)
WO (1)	WO1988010264A1 (de)

Families Citing this family (872)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4948882A (en) *	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US5047519A (en) *	1986-07-02	1991-09-10	E. I. Du Pont De Nemours And Company	Alkynylamino-nucleotides
US5824796A (en) *	1988-09-28	1998-10-20	Epoch Pharmaceuticals, Inc.	Cross-linking oligonucleotides
US5849482A (en) *	1988-09-28	1998-12-15	Epoch Pharmaceuticals, Inc.	Crosslinking oligonucleotides
USRE38416E1 (en)	1988-09-28	2004-02-03	Epoch Biosciences, Inc.	Cross-linking oligonucleotides
FR2642074B1 (fr) *	1989-01-20	1994-04-29	Oris Ind	Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide
EP0472648A4 (en) *	1989-05-18	1992-09-16	Microprobe Corporation	Crosslinking oligonucleotides
US6013434A (en) *	1989-12-22	2000-01-11	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates
WO1993024511A1 (en) *	1992-05-29	1993-12-09	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates
DE4102289A1 (de) *	1991-01-26	1992-07-30	Bayer Ag	Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
US6136601A (en) *	1991-08-21	2000-10-24	Epoch Pharmaceuticals, Inc.	Targeted mutagenesis in living cells using modified oligonucleotides
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US6235887B1 (en) *	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
AU678968B2 (en) *	1992-05-29	1997-06-19	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates
AU679566B2 (en)	1993-09-03	1997-07-03	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US6028190A (en)	1994-02-01	2000-02-22	The Regents Of The University Of California	Probes labeled with energy transfer coupled dyes
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US6008373A (en)	1995-06-07	1999-12-28	Carnegie Mellon University	Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US5945526A (en)	1996-05-03	1999-08-31	Perkin-Elmer Corporation	Energy transfer dyes with enhanced fluorescence
US7825237B2 (en) *	1996-05-03	2010-11-02	Applied Biosystems, Llc	Oligonucleotides and analogs labeled with energy transfer dyes
US7388092B2 (en) *	1996-05-03	2008-06-17	Applera Corporation	Oligonucleotides and analogs labeled with energy transfer dyes
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
SE9701783D0 (sv) *	1997-05-14	1997-05-14	Marek Kwiatkowski	In situ synthesis of oligonucleotides of inverse orientation
CA2294988C (en)	1997-07-01	2015-11-24	Isis Pharmaceuticals Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6007992A (en) *	1997-11-10	1999-12-28	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US6028183A (en)	1997-11-07	2000-02-22	Gilead Sciences, Inc.	Pyrimidine derivatives and oligonucleotides containing same
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
JP2002515514A (ja)	1998-05-21	2002-05-28	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの局所送逹のための組成物及び方法
WO1999060012A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6358684B1 (en) *	1999-08-27	2002-03-19	Pe Corporation	UV excitable fluorescent energy transfer dyes
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6436641B1 (en) *	2000-04-17	2002-08-20	Visible Genetics Inc.	Method and apparatus for DNA sequencing
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (de)	2000-10-12	2003-07-16	University of Rochester	Zusammensetzungen die die proliferation von krebszellen hemmen
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7083951B2 (en) *	2001-02-14	2006-08-01	The Regents Of The University Of California	Flow cytometric detection method for DNA samples
US6573051B2 (en) *	2001-03-09	2003-06-03	Molecular Staging, Inc.	Open circle probes with intramolecular stem structures
ES2372321T3 (es)	2001-06-20	2012-01-18	Genentech, Inc.	Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
EP2270024B1 (de)	2001-06-21	2018-10-24	Ionis Pharmaceuticals, Inc.	Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
ATE486092T1 (de)	2001-09-18	2010-11-15	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US20030228319A1 (en)	2002-04-16	2003-12-11	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
GB0128526D0 (en) *	2001-11-29	2002-01-23	Amersham Pharm Biotech Uk Ltd	Nucleotide analogues
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
AU2002367318B2 (en)	2002-01-02	2007-07-12	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7553619B2 (en)	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20050287648A1 (en)	2002-08-05	2005-12-29	University Of Rochester	Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US7794931B2 (en) *	2002-09-20	2010-09-14	Yale University	Riboswitches, methods for their use, and compositions for use with riboswitches
EP2272958A1 (de)	2002-09-26	2011-01-12	ISIS Pharmaceuticals, Inc.	Modulierung von der Forkheadbox O1A-Expression
AU2003287505A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
PT2336318E (pt)	2002-11-13	2013-06-12	Genzyme Corp	Modulação anti-sentido da expressão de apolipoproteína b
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
ATE444359T1 (de)	2002-11-15	2009-10-15	Morphotek Inc	Verfahren zur erzeugung einer hohen antikörperproduktion von durch in-vitro- immunisierung entstandenen hybridomen
JP4915980B2 (ja)	2002-11-15	2012-04-11	エムユーエスシーファウンデーションフォーリサーチデベロップメント	補体レセプター２標的化補体調節因子
CA2507044A1 (en)	2002-11-21	2004-06-10	Mary Lucero	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121338A1 (en) *	2002-12-19	2004-06-24	Alsmadi Osama A.	Real-time detection of rolling circle amplification products
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
AU2003299694A1 (en)	2002-12-20	2004-07-22	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
US7781163B2 (en) *	2003-01-08	2010-08-24	Lesley Davenport	G-quadruplex binding assays and compounds therefor
CA2515484C (en)	2003-02-11	2011-09-20	Antisense Therapeutics Ltd	Modulation of insulin like growth factor i receptor expression
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
CA2540692C (en)	2003-06-02	2013-05-28	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
JP4579911B2 (ja)	2003-06-03	2010-11-10	アイシス・ファーマシューティカルズ・インコーポレイテッド	スルビビン発現の調節
EP1633770B1 (de)	2003-06-13	2015-04-29	Alnylam Europe AG	Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
KR101218889B1 (ko)	2003-08-27	2013-01-11	옵쏘테크 코포레이션	안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005027962A1 (en)	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
US7425544B2 (en)	2003-09-18	2008-09-16	Eli Lilly And Company	Modulation of eIF4E expression
CN1882602B (zh)	2003-10-10	2011-02-09	阿尔卡米亚肿瘤股份有限公司	在疾病治疗中乙酰透明质酸合成的调节和降解
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
AU2004291141B2 (en)	2003-11-17	2009-06-11	Genentech, Inc.	Compositions and methods for the treatment of tumor of hematopoietic origin
JP2007520222A (ja)	2004-01-20	2007-07-26	アイシスファーマシューティカルズインコーポレイテッド	グルココルチコイドレセプター発現の調節
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1730309B1 (de)	2004-03-15	2016-05-04	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur optimierung der spaltung von rna durch rnase h
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
JP4584987B2 (ja)	2004-04-30	2010-11-24	アルニラムファーマスーティカルズインコーポレイテッド	Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
CA2564251C (en)	2004-05-21	2018-04-10	The Uab Research Foundation	Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7427675B2 (en)	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
CA2623471C (en)	2004-09-23	2018-02-13	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
EP1869076A2 (de)	2005-03-10	2007-12-26	Genentech, Inc.	Verfahren und zusammensetzungen zur modulation der gefässintegrität
US7476733B2 (en)	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8252756B2 (en)	2005-06-14	2012-08-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
DK1929012T3 (da)	2005-08-11	2011-01-31	Synthetic Genomics Inc	Fremgangsmåde til in vitro-rekombination
CA2617693A1 (en)	2005-08-17	2007-02-22	Medexis S.A.	Composition and method for determination of ck19 expression
AU2006284855B2 (en)	2005-08-29	2011-10-13	Regulus Therapeutics Inc.	Methods for use in modulating miR-122a
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
AU2006292217A1 (en)	2005-09-19	2007-03-29	Isis Pharmaceuticals, Inc.	Modulation of glucagon receptor expression
AU2006292293B2 (en)	2005-09-19	2012-09-13	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2392647A1 (de)	2005-10-14	2011-12-07	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
WO2007051045A2 (en)	2005-10-28	2007-05-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
ATE510545T1 (de)	2005-11-09	2011-06-15	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
EP1966377A2 (de)	2005-11-21	2008-09-10	Isis Pharmaceuticals, Inc.	Modulation der eif4e-bp2-expression
EP1974052A2 (de) *	2005-12-21	2008-10-01	Yale University	Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
CN101437933B (zh)	2005-12-28	2013-11-06	斯克里普斯研究所	作为药物靶标的天然反义和非编码的rna转录物
CA2640058C (en)	2006-01-27	2018-04-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
KR101304071B1 (ko) *	2006-01-27	2013-09-06	아이시스 파마수티컬즈 인코포레이티드	6-변형된 바이시클릭 핵산 유사체
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
WO2007115168A2 (en)	2006-03-31	2007-10-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of eg5 gene
EP2013344B1 (de)	2006-05-03	2012-08-29	Baltic Technology Development, Ltd.	Antisense-agentien mit kombination von mit stark gebundener base modifiziertem oligonukleotid und künstlicher nuklease
WO2007143317A2 (en)	2006-05-05	2007-12-13	Isis Pharmaceuticals, Inc	Compounds and methods for modulating expression of crp
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
WO2007134181A2 (en)	2006-05-11	2007-11-22	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
US7812150B2 (en)	2006-05-19	2010-10-12	Alnylam Pharmaceuticals, Inc.	RNAi modulation of Aha and therapeutic uses thereof
WO2007137220A2 (en)	2006-05-22	2007-11-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
EP2061799A4 (de) *	2006-09-11	2010-12-22	Univ Yale	Verfahren und zusammensetzungen zur verwendung von lysin-riboswitches
US20100099858A1 (en) *	2006-09-28	2010-04-22	Mirkin Chad A	Maximizing Oligonucleotide Loading on Gold Nanoparticle
US7947487B2 (en)	2006-10-05	2011-05-24	Massachusetts Institute Of Technology	Multifunctional encoded particles for high-throughput analysis
US8999317B2 (en)	2006-11-01	2015-04-07	University Of Rochester	Methods and compositions related to the structure and function of APOBEC3G
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
CA2691066C (en)	2007-02-09	2018-07-31	Northwestern University	Particles for detecting intracellular targets
KR20100015757A (ko)	2007-03-22	2010-02-12	예일 유니버시티	택일적 스플라이싱을 조절하는 리보스위치와 관련된 방법 및 조성물
AP3018A (en)	2007-03-29	2014-10-31	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expressionof a gene from the ebola
EP2164994A4 (de) *	2007-05-29	2010-07-21	Univ Yale Inc	Verfahren und zusammensetzungen in verbindung mit riboswitches zu steuerung von alternativer spleissung und rna-verarbeitung
US20100286082A1 (en) *	2007-05-29	2010-11-11	Yale University	Riboswitches and methods and compositions for use of and with riboswitches
ES2388590T3 (es)	2007-05-30	2012-10-16	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
CA2689923A1 (en)	2007-05-30	2008-12-11	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
WO2008154401A2 (en)	2007-06-08	2008-12-18	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
ATE538127T1 (de) *	2007-07-05	2012-01-15	Isis Pharmaceuticals Inc	6-disubstituierte bicyclische nukleinsäureanaloga
US8088904B2 (en) *	2007-08-15	2012-01-03	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
JP2010538005A (ja)	2007-08-28	2010-12-09	ユーエービーリサーチファウンデーション	合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
CA2697957A1 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en)	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
WO2009067243A2 (en)	2007-11-20	2009-05-28	Isis Pharmaceuticals Inc.	Modulation of cd40 expression
AU2008335202A1 (en)	2007-12-10	2009-06-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Factor VII gene
EP2224912B1 (de)	2008-01-02	2016-05-11	TEKMIRA Pharmaceuticals Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
US8530640B2 (en) *	2008-02-07	2013-09-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
SG188121A1 (en)	2008-03-05	2013-03-28	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of eg5 and vegf genes
US8426378B2 (en) *	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US9290534B2 (en) *	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
WO2009124295A2 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
MX2010011508A (es)	2008-04-18	2011-05-03	Baxter Int	Composicion basada en microesferas para prevenir y/o revertir la nueva presentacion de diabetes autoinmune.
BRPI0916440A2 (pt) *	2008-07-15	2018-06-05	Hoffmann La Roche	composições e métodos para inibir a expressão dos genes receptores tgf-beta
EP3081648A1 (de)	2008-08-25	2016-10-19	Excaliard Pharmaceuticals, Inc.	Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
WO2010028079A2 (en) *	2008-09-02	2010-03-11	Alnylam Pharmaceuticals, Inc	Synthetic methods and derivatives of triphosphate oligonucleotides
EP3208337A1 (de)	2008-09-02	2017-08-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
US8604192B2 (en) *	2008-09-24	2013-12-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acids analogs
EP3584320A1 (de)	2008-09-25	2019-12-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
EP2743265B1 (de)	2008-10-09	2017-03-15	Arbutus Biopharma Corporation	Verbesserte Aminolipide und Verfahren zur Freisetzung von Nukleinsäuren
JP5809058B2 (ja)	2008-10-15	2015-11-10	アイシスファーマシューティカルズ，インコーポレーテッド	第１１因子発現の調節
DK2344639T3 (en)	2008-10-20	2015-07-27	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETINE
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
WO2010048549A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
SG171737A1 (en) *	2008-11-17	2011-07-28	Hoffmann La Roche	Compositions and methods for inhibiting expression of factor vii genes
CA2744207C (en)	2008-11-24	2019-05-28	Northwestern University	Polyvalent rna-nanoparticle compositions
RU2572826C2 (ru)	2008-12-02	2016-01-20	Чиралджен, Лтд.	Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
ES2760912T3 (es)	2008-12-04	2020-05-18	Curna Inc	Tratamiento de enfermedades relacionadas con la Sirtuina 1 (SIRT1) por inhibición del transcrito antisentido natural de la Sirtuina 1
JP6091752B2 (ja)	2008-12-04	2017-03-08	クルナ・インコーポレーテッド	Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
KR20110091796A (ko)	2008-12-04	2011-08-12	오피케이오 큐알엔에이, 엘엘씨	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CA2746514C (en)	2008-12-10	2018-11-27	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
EP2391733A1 (de)	2009-01-27	2011-12-07	QIAGEN Gaithersburg, Inc.	Thermophile-helikase-abhängige amplifikationstechnik mit homogenem fluoreszenzendpunktnachweis
EP2391343B1 (de)	2009-01-29	2017-03-01	Arbutus Biopharma Corporation	Verbesserte lipidformulierung zur verabreichung von nukleinsaueren
AU2010211133A1 (en) *	2009-02-03	2011-07-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of PTP1B genes
WO2010090969A1 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
WO2010091308A2 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
ES2560107T3 (es)	2009-02-12	2016-02-17	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
CN102439149B (zh)	2009-02-12	2018-01-02	库尔纳公司	通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
JP6250263B2 (ja)	2009-03-04	2017-12-20	クルナ・インコーポレーテッド	サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるｓｉｒｔ１関連疾患の治療
EP2406376A1 (de)	2009-03-12	2012-01-18	Alnylam Pharmaceuticals, Inc.	Lipidformulierte zusammensetzungen und verfahren zur hemmung der expression von eg5- und vegf-genen
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
MX2011009752A (es)	2009-03-17	2011-09-29	Opko Curna Llc	Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
CN108451968A (zh)	2009-04-15	2018-08-28	西北大学	寡核苷酸功能化的纳米颗粒的递送
EP3524275A1 (de)	2009-04-22	2019-08-14	Massachusetts Institute Of Technology	Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
EP2424987B1 (de)	2009-05-01	2017-11-15	CuRNA, Inc.	Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
CA3151387A1 (en)	2009-05-05	2010-11-11	Arbutus Biopharma Corporation	Lipid compositions for the delivery of therapeutic agents
EP3504967A1 (de)	2009-05-05	2019-07-03	Arbutus Biopharma Corporation	Verfahren zur abgabe von oligonukleotiden an immunzellen
WO2010129799A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
JP6250930B2 (ja)	2009-05-06	2017-12-20	クルナ・インコーポレーテッド	トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
MX2011011395A (es) *	2009-05-15	2011-11-18	Hoffmann La Roche	Composiciones y metodos para inhibir la expresion de genes de receptor de glucocorticoide.
EP2430161A1 (de)	2009-05-15	2012-03-21	Yale University	Gemm-riboswitches, strukturbasierte verbindungskonstruktion mit gemm-riboswitches sowie verfahren und zusammensetzungen zur verwendung von und mit gemm-riboswitches
US8957037B2 (en)	2009-05-18	2015-02-17	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (ko)	2009-05-22	2017-02-08	큐알엔에이, 인크.	전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CN103221541B (zh)	2009-05-28	2017-03-01	库尔纳公司	通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
NZ712719A (en)	2009-06-10	2017-03-31	Arbutus Biopharma Corp	Improved lipid formulation
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
US8951981B2 (en)	2009-06-16	2015-02-10	Curna, Inc.	Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
JP5907866B2 (ja)	2009-06-26	2016-04-26	クルナ・インコーポレーテッド	ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
SG10201403841QA (en)	2009-07-06	2014-09-26	Ontorii Inc	Novel nucleic acid prodrugs and methods of use thereof
ES2645754T3 (es) *	2009-07-30	2017-12-07	F. Hoffmann-La Roche Ag	Conjunto de sondas de oligonucleótidos así como métodos y usos relacionados con el mismo
WO2011017516A2 (en)	2009-08-05	2011-02-10	Curna, Inc.	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011017521A2 (en)	2009-08-06	2011-02-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
AP3574A (en)	2009-08-14	2016-02-08	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
JP5964232B2 (ja)	2009-08-25	2016-08-03	カッパーアールエヌエー，インコーポレイテッド	‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
BR112012009409A2 (pt)	2009-10-22	2017-02-21	Genentech Inc	método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
AU2010315399B2 (en)	2009-10-27	2016-01-28	Swift Biosciences, Inc.	Bimolecular primers
US9376690B2 (en)	2009-10-30	2016-06-28	Northwestern University	Templated nanoconjugates
WO2011056215A1 (en)	2009-11-03	2011-05-12	Landers James P	Versatile, visible method for detecting polymeric analytes
US20110112176A1 (en) *	2009-11-09	2011-05-12	John Frederick Boylan	Compositions and methods for inhibiting expression of kif10 genes
CA2781469A1 (en)	2009-11-23	2011-05-26	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
SG10201408598XA (en)	2009-11-30	2015-02-27	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
DK2513310T3 (en)	2009-12-16	2018-02-05	Curna Inc	TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
US20110152349A1 (en)	2009-12-18	2011-06-23	Anke Geick	Compositions and methods for inhibiting expression of il-18 genes
ES2661387T3 (es)	2009-12-23	2018-03-28	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
CA2782375C (en)	2009-12-23	2023-10-31	Opko Curna, Llc	Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
JP5993744B2 (ja)	2009-12-29	2016-09-14	カッパーアールエヌエー，インコーポレイテッド	核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
EP2519634B1 (de)	2009-12-29	2016-06-01	CuRNA, Inc.	Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko)	2010-01-06	2018-04-30	큐알엔에이, 인크.	췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR101854926B1 (ko)	2010-01-11	2018-05-04	큐알엔에이, 인크.	성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
US8779118B2 (en)	2010-01-11	2014-07-15	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011088076A2 (en)	2010-01-12	2011-07-21	Yale University	Structured rna motifs and compounds and methods for their use
ES2671877T3 (es)	2010-01-25	2018-06-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
TW201129365A (en) *	2010-02-05	2011-09-01	Hoffmann La Roche	Compositions and methods for inhibiting expression of IKK2 genes
ES2600356T3 (es)	2010-02-22	2017-02-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
NZ601293A (en)	2010-02-23	2014-10-31	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP3210611B1 (de)	2010-03-12	2019-08-21	The Brigham and Women's Hospital, Inc.	Verfahren zur behandlung von gefässentzündungserkrankungen
WO2011113054A2 (en)	2010-03-12	2011-09-15	Aurasense Llc	Crosslinked polynucleotide structure
WO2011115817A1 (en)	2010-03-16	2011-09-22	Isis Pharmaceuticals, Inc.	Methods of preparing 2'-o-substituted purine nucleosides
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011120046A2 (en)	2010-03-26	2011-09-29	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
ES2893199T3 (es)	2010-03-29	2022-02-08	Alnylam Pharmaceuticals Inc	Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
JP2013523162A (ja)	2010-04-06	2013-06-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
JP5978203B2 (ja)	2010-04-09	2016-08-24	カッパーアールエヌエー，インコーポレイテッド	Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133876A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011139695A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
CN103154014B (zh)	2010-04-28	2015-03-25	Isis制药公司	修饰核苷、其类似物以及由它们制备的寡聚化合物
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
US20110294868A1 (en)	2010-04-29	2011-12-01	Monia Brett P	Modulation of transthyretin expression
EP2957636B1 (de)	2010-05-03	2020-04-01	CuRNA, Inc.	Behandlung von sirtuin 3 (sirt3)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt3
RU2636461C2 (ru)	2010-05-03	2017-11-23	Дженентек, Инк.	Композиции и способы для диагностики и лечения опухоли
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
US8895528B2 (en)	2010-05-26	2014-11-25	Curna, Inc.	Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
WO2011150227A1 (en)	2010-05-26	2011-12-01	Qiagen Gaithersburg, Inc.	Quantitative helicase assay
AU2011261434B2 (en)	2010-06-02	2015-11-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156434A2 (en)	2010-06-07	2011-12-15	Firefly Bioworks, Inc.	Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156202A1 (en)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
EP2582397A4 (de)	2010-06-15	2014-10-29	Isis Pharmaceuticals Inc	Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
JP5998131B2 (ja)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
EP2595664B1 (de)	2010-07-19	2018-10-17	Ionis Pharmaceuticals, Inc.	Modulation einer kern-rna
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
JP5974012B2 (ja)	2010-10-05	2016-08-23	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
US8993533B2 (en)	2010-10-06	2015-03-31	Curna, Inc.	Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
WO2012052258A1 (en)	2010-10-18	2012-04-26	Arrowhead Research Corporation	Compositions and methods for inhibiting expression of rrm2 genes
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
RU2611195C2 (ru)	2010-10-27	2017-02-21	Курна, Инк.	Лечение заболеваний, связанных с интерферон- связанным регулятором развития 1 (ifrd1), путем ингибирования природного антисмыслового транскрипта к ifrd1
WO2012064824A1 (en)	2010-11-09	2012-05-18	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
US9328346B2 (en)	2010-11-12	2016-05-03	The General Hospital Corporation	Polycomb-associated non-coding RNAs
AU2011329777B2 (en)	2010-11-17	2016-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
JP6071893B2 (ja)	2010-11-23	2017-02-01	カッパーアールエヌエー，インコーポレイテッド	Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9127275B2 (en)	2010-12-10	2015-09-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2012078967A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (epo) production
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
SI2670411T1 (sl)	2011-02-02	2019-06-28	Excaliard Pharmaceuticals, Inc.	Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
EP3369828B1 (de)	2011-02-07	2020-07-15	The Governing Council Of The University Of Toronto	Biosonden und verfahren zur verwendung davon
EP2673361B1 (de)	2011-02-08	2016-04-13	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und ihre verwendung
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
KR102365961B1 (ko)	2011-03-29	2022-02-23	알닐람 파마슈티칼스 인코포레이티드	Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
JP2014511694A (ja)	2011-04-03	2014-05-19	ザジェネラルホスピタルコーポレーションドゥーイングビジネスアズマサチューセッツジェネラルホスピタル	修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
US20140186844A1 (en)	2011-04-26	2014-07-03	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151324A1 (en)	2011-05-02	2012-11-08	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
ES2653247T3 (es)	2011-06-09	2018-02-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
KR20230084331A (ko)	2011-06-21	2023-06-12	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
MX360782B (es)	2011-06-21	2018-11-16	Alnylam Pharmaceuticals Inc	Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
EP3388068A1 (de)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
EP2723390B1 (de)	2011-06-23	2017-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
US9222093B2 (en)	2011-06-30	2015-12-29	The University Of Hong Kong	Two-way, portable riboswitch mediated gene expression control device
CN113430196B (zh)	2011-06-30	2025-05-20	箭头药业股份有限公司	用于抑制乙型肝炎病毒的基因表达的组合物和方法
CN107365339A (zh)	2011-07-19	2017-11-21	波涛生命科学有限公司	合成官能化核酸的方法
WO2013019857A2 (en)	2011-08-01	2013-02-07	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
EP2742136B1 (de)	2011-08-11	2017-09-27	Ionis Pharmaceuticals, Inc.	Gapmerverbindungen mit 5'-modifizierten desoxyribonukleotiden im gap und verwendungen davon
EP2751269B1 (de)	2011-08-29	2016-03-23	Ionis Pharmaceuticals, Inc.	Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
EP2751270B1 (de)	2011-08-29	2018-08-22	Ionis Pharmaceuticals, Inc.	Oligomer-konjugat-komplexe und ihre verwendung
EP2755692B1 (de)	2011-09-14	2020-11-25	Northwestern University	Nanokonjugate zur durchquerung der blut-hirn-schranke
CA2848753C (en)	2011-09-14	2022-07-26	Rana Therapeutics, Inc.	Multimeric oligonucleotide compounds
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
WO2013055865A1 (en)	2011-10-11	2013-04-18	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
WO2013090457A2 (en)	2011-12-12	2013-06-20	Oncoimmunin Inc.	In vivo delivery of oligonucleotides
EP2794627B1 (de)	2011-12-22	2018-09-26	Alios Biopharma, Inc.	Substituierte nukleoside, nukleotide und analoga davon
IL321422A (en)	2012-01-11	2025-08-01	Ionis Pharmaceuticals Inc	Compositions and methods for modulation of ikbkap splicing
CA2866625C (en)	2012-03-13	2020-12-08	Swift Biosciences, Inc.	Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
HUE040179T2 (hu)	2012-03-15	2019-02-28	Curna Inc	Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
CA2907072A1 (en)	2012-03-16	2013-09-19	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of dmpk
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
AU2013203395A1 (en)	2012-03-30	2013-10-17	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
WO2013154798A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
HK1211316A1 (en)	2012-04-20	2016-05-20	艾珀特玛治疗公司	Mirna modulators of thermogenesis
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP3597741A1 (de)	2012-04-27	2020-01-22	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
WO2013173638A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating smn gene family expression
CA2873809A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en)	2012-05-17	2016-01-07	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9487780B2 (en)	2012-06-01	2016-11-08	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013181665A1 (en)	2012-06-01	2013-12-05	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20130330389A1 (en)	2012-06-08	2013-12-12	The Regents Of The University Of Michigan	Ultrasound-triggerable agents for tissue engineering
RU2693381C2 (ru)	2012-07-13	2019-07-02	Уэйв Лайф Сайенсес Лтд.	Асимметричная вспомогательная группа
EP2872147B1 (de)	2012-07-13	2022-12-21	Wave Life Sciences Ltd.	Verfahren zur herstellung von chiralen oligonukleotiden
WO2014010718A1 (ja)	2012-07-13	2014-01-16	株式会社新日本科学	キラル核酸アジュバント
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
KR102237882B1 (ko)	2012-08-15	2021-04-07	아이오니스 파마수티컬즈, 인코포레이티드	변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
US9499817B2 (en)	2012-09-06	2016-11-22	The University Of Chicago	Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
EP2906255B1 (de)	2012-10-12	2023-02-22	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
US20150275208A1 (en)	2012-10-12	2015-10-01	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
HK1214293A1 (zh)	2012-10-26	2016-07-22	Geron Corporation	C-myc反义寡核苷酸和利用其治疗细胞增殖性疾病的方法
ES2949394T3 (es)	2012-11-05	2023-09-28	Found Medicine Inc	Moléculas de fusión novedosas y usos de las mismas
WO2014071358A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
WO2014093537A1 (en)	2012-12-11	2014-06-19	Isis Pharmaceuticals, Inc.	Competitive modulation of micrornas
CA3150658A1 (en)	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
ES2817050T3 (es)	2013-02-04	2021-04-06	Ionis Pharmaceuticals Inc	Compuestos antisentido selectivos y usos de los mismos
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
BR112015022308A8 (pt)	2013-03-14	2018-01-23	Andes Biotechnologies S A	oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas
SG10201912286TA (en)	2013-03-14	2020-02-27	Alnylam Pharmaceuticals Inc	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20150130430A (ko)	2013-03-14	2015-11-23	아이시스 파마수티컬즈 인코포레이티드	타우 발현을 조절하는 조성물 및 방법
CN105283466A (zh)	2013-03-14	2016-01-27	安第斯生物技术股份有限公司	用于检测和治疗多发性骨髓瘤的方法
WO2014152054A1 (en)	2013-03-15	2014-09-25	Bio-Rad Laboratories, Inc.	Digital assays for mutation detection
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
US9937231B2 (en)	2013-03-27	2018-04-10	The General Hospital Corporation	Methods and agents for treating Alzheimer's disease
EP2981617B1 (de)	2013-04-04	2023-07-05	President and Fellows of Harvard College	Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen
US9677075B2 (en)	2013-04-23	2017-06-13	Northwestern University	Metal-ligand coordination polymer nanoparticles and methods for making
DK2991656T3 (da)	2013-05-01	2020-03-23	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
CN113018307A (zh)	2013-05-22	2021-06-25	阿尔尼拉姆医药品有限公司	SERPINA1 iRNA组合物及其使用方法
AP2015008862A0 (en)	2013-05-22	2015-11-30	Alnylam Pharmaceuticals Inc	Tmprss6 irna compositions and methods of use thereof
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
DK3007704T3 (da)	2013-06-13	2021-03-29	Antisense Therapeutics Ltd	Kombinationsterapi til akromegali
AU2014284152B2 (en)	2013-06-21	2020-01-23	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
EP3022176B8 (de)	2013-07-15	2019-12-25	The Regents of the University of California	Eingeschränkte azacyclische analoga von fty720
TWI657819B (zh)	2013-07-19	2019-05-01	美商Ionis製藥公司	用於調節τ蛋白表現之組合物
CA2919268C (en)	2013-07-25	2023-09-05	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
DK3041854T3 (da)	2013-08-08	2020-03-02	Scripps Research Inst	En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US9943604B2 (en)	2013-09-20	2018-04-17	Ionis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
EP3052626A1 (de)	2013-10-02	2016-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
US10119143B2 (en)	2013-10-04	2018-11-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
US9988627B2 (en)	2013-10-04	2018-06-05	Novartis Ag	Formats for organic compounds for use in RNA interference
CN105792832B (zh)	2013-10-04	2021-03-23	诺华股份有限公司	用于治疗乙肝病毒的有机化合物
WO2015051045A2 (en)	2013-10-04	2015-04-09	Novartis Ag	3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
WO2015054451A1 (en)	2013-10-09	2015-04-16	The United States Of America As Represented By The Secretary Department Of Health And Human Services	Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
US10053692B2 (en)	2013-10-21	2018-08-21	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
US10301622B2 (en)	2013-11-04	2019-05-28	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
DK3066219T3 (en)	2013-11-08	2019-03-11	Ionis Pharmaceuticals Inc	METHODS FOR DETECTING OIGONUCLEOTIDES
CA2931829A1 (en)	2013-12-02	2015-06-11	Ionis Pharmaceuticals, Inc.	Antisense compounds and uses thereof
CA2932122C (en)	2013-12-03	2022-04-19	Northwestern University	Liposomal particles, methods of making same and uses thereof
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
MX382900B (es)	2013-12-12	2025-03-13	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE ÁCIDO RIBONUCLEICO DE INTERFERENCIA (ARNi) CONTRA EL COMPONENTE DEL COMPLEMENTO Y MÉTODOS PARA SU USO.
CN106456694B (zh)	2013-12-20	2020-06-30	通用医疗公司	与循环肿瘤细胞相关的方法和测定法
EP3095459A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
CA2936712A1 (en)	2014-01-16	2015-07-23	Meena	Chiral design
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
AU2015217301A1 (en)	2014-02-11	2016-08-25	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
US10036019B2 (en)	2014-03-17	2018-07-31	Ionis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
RU2702838C2 (ru)	2014-03-19	2019-10-11	Ионис Фармасьютикалз, Инк.	Композиции для модуляции экспрессии атаксина 2
EP3757214B1 (de)	2014-04-01	2022-06-15	Biogen MA Inc.	Zusammensetzungen zur modulierung der sod-1-expression
HUE056155T2 (hu)	2014-04-09	2022-01-28	Scripps Research Inst	Nem-természetes vagy módosított nukleozid-trifoszfátok sejtekbe importálása nukleinsav-trifoszfát transzporterekkel
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP3137476B1 (de)	2014-04-28	2019-10-09	Ionis Pharmaceuticals, Inc.	Verbindungsmodifizierte oligomerverbindungen
JP2017521045A (ja)	2014-05-01	2017-08-03	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アンジオポエチン様因子３発現を調節するための組成物及び方法
CR20200228A (es)	2014-05-01	2020-07-09	Ionis Pharmaceuticals Inc	COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
KR102149571B1 (ko)	2014-05-01	2020-08-31	아이오니스 파마수티컬즈, 인코포레이티드	성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
CN106574268B (zh)	2014-05-22	2021-02-05	阿尔尼拉姆医药品有限公司	血管紧张素原（AGT）iRNA组合物及其使用方法
WO2015179693A1 (en)	2014-05-22	2015-11-26	Isis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
JP2017518307A (ja)	2014-06-02	2017-07-06	チルドレンズメディカルセンターコーポレーション	免疫調節のための方法および組成物
EP3508198A1 (de)	2014-06-04	2019-07-10	Exicure, Inc.	Multivalente ausgabe von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
WO2015190922A1 (en)	2014-06-10	2015-12-17	Erasmus University Medical Center Rotterdam	Antisense oligonucleotides useful in treatment of pompe disease
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
AU2015298263B2 (en)	2014-07-31	2020-05-14	Anji Pharmaceuticals, Inc.	ApoE mimetic peptides and higher potency to clear plasma cholesterol
US12264344B2 (en)	2014-08-19	2025-04-01	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
US9617541B2 (en)	2014-08-20	2017-04-11	Northwestern University	Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
PL3185957T3 (pl)	2014-08-29	2022-11-14	Alnylam Pharmaceuticals, Inc.	Patisiran do zastosowania w leczeniu amyloidozy związanej z transtyretyną
JP2017526367A (ja)	2014-08-29	2017-09-14	チルドレンズメディカルセンターコーポレーション	癌の処置のための方法および組成物
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016040748A1 (en)	2014-09-12	2016-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3198012B1 (de)	2014-09-26	2019-09-04	University of Massachusetts	Rna-modulierende stoffe
TWI755351B (zh)	2014-10-10	2022-02-21	美商艾爾妮蘭製藥公司	用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
HRP20192177T1 (hr)	2014-11-10	2020-02-21	Alnylam Pharmaceuticals, Inc.	Rnai pripravci za virus hepatitisa b (hbv) i postupci njihove upotrebe
WO2016077540A1 (en)	2014-11-12	2016-05-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of comp
WO2016077837A1 (en)	2014-11-14	2016-05-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of proteins
CN113846101A (zh)	2014-11-17	2021-12-28	阿尔尼拉姆医药品有限公司	载脂蛋白C3（APOC3）iRNA组合物及其使用方法
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3229842B1 (de)	2014-12-08	2022-07-06	The Board of Regents of The University of Texas System	Lipokationische polymere und verwendungen davon
US12359197B2 (en)	2014-12-12	2025-07-15	Etagen Pharma, Inc.	Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
EP3247988A4 (de)	2015-01-23	2018-12-19	Vanderbilt University	Robustes interferometer und verfahren zur verwendung davon
EP3256487A4 (de)	2015-02-09	2018-07-18	Duke University	Zusammensetzungen und verfahren zur epigenombearbeitung
JP2018510621A (ja)	2015-02-13	2018-04-19	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
WO2016135559A2 (en)	2015-02-23	2016-09-01	Crispr Therapeutics Ag	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
CN115537396A (zh)	2015-03-27	2022-12-30	哈佛学院校长同事会	经过修饰的t细胞及其制备和使用方法
WO2016164463A1 (en)	2015-04-07	2016-10-13	The General Hospital Corporation	Methods for reactivating genes on the inactive x chromosome
DK3283500T3 (en)	2015-04-08	2020-11-16	Univ Chicago	Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
CA2991045A1 (en)	2015-06-29	2017-01-05	Caris Science, Inc.	Therapeutic oligonucleotides binding c1q
EP4545544A3 (de)	2015-06-29	2025-10-08	Ionis Pharmaceuticals, Inc.	Modifizierte crispr-rna und modifizierte single-crispr-rna und verwendungen davon
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
EP3320094B1 (de)	2015-07-10	2022-04-13	Ionis Pharmaceuticals, Inc.	Modulatoren der diacyglycerol-acyltransferase (2 dgat2)
CR20180107A (es)	2015-07-22	2018-04-03	Wave Life Sciences Ltd	Composiciones de oligonucleótidos y métodos de los mismos
WO2017019918A1 (en)	2015-07-28	2017-02-02	Caris Science, Inc.	Targeted oligonucleotides
US20180237774A1 (en)	2015-08-04	2018-08-23	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
JP7336191B2 (ja)	2015-08-07	2023-08-31	アローヘッドファーマシューティカルズインコーポレイテッド	Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法
EP4393495A3 (de)	2015-09-02	2024-09-25	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit programmiertem zelltod 1-ligand 1 (pd-l1) und verfahren zur verwendung davon
KR102641298B1 (ko)	2015-09-14	2024-03-04	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	지질양이온성 덴드리머 및 이의 용도
AR106135A1 (es)	2015-09-24	2017-12-13	Ionis Pharmaceuticals Inc	Moduladores de la expresión del sarcoma de la rata de kirsten (kras)
EP3353297A1 (de)	2015-09-24	2018-08-01	Crispr Therapeutics AG	Neuartige familie von rna-programmierbaren endonukleasen und deren verwendung in der genomeditierung und anderen anwendungen
EP3352753A4 (de)	2015-09-24	2019-03-13	The Regents of The University of California	Synthetische sphingolipid-ähnliche moleküle, arzneimittel, verfahren zu deren synthese und behandlungsverfahren
EP3353303B1 (de)	2015-09-25	2023-08-02	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
US10709812B2 (en)	2015-09-29	2020-07-14	The Regents Of The University Of Michigan	Biodegradable hydrogel for tissue expansion
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
EP4632068A3 (de)	2015-10-28	2026-01-21	Vertex Pharmaceuticals Inc.	Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
CA3007424A1 (en)	2015-11-05	2017-05-11	Children's Hospital Los Angeles	"mobilizing leukemia cells"
CN113952353A (zh)	2015-11-06	2022-01-21	Ionis制药公司	调节载脂蛋白(a)表达
SMT202400375T1 (it)	2015-11-06	2024-11-15	Ionis Pharmaceuticals Inc	Composti antisenso coniugati per uso in terapia
MX2018005332A (es)	2015-11-06	2018-11-09	Crispr Therapeutics Ag	Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
WO2017087708A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EA201891317A3 (ru)	2015-11-30	2019-04-30	Дьюк Юниверсити	Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
JP6932698B2 (ja)	2015-12-01	2021-09-08	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	アルファ１アンチトリプシン欠乏症の治療のための材料および方法
WO2017096395A1 (en)	2015-12-04	2017-06-08	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
EP3387127A1 (de)	2015-12-07	2018-10-17	Erasmus University Medical Center Rotterdam	Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit
IL259795B2 (en)	2015-12-07	2024-04-01	Genzyme Corp	Methods and compositions for treating a serpinc1-associated disorder
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
CA3009308A1 (en)	2015-12-23	2017-06-29	Chad Albert COWAN	Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
CA3006015A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
WO2017132483A1 (en)	2016-01-29	2017-08-03	Vanderbilt University	Free-solution response function interferometry
WO2017134529A1 (en)	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
EP3416689B1 (de)	2016-02-18	2023-01-18	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
US11234996B2 (en)	2016-02-25	2022-02-01	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting SMOC2
CA3016592A1 (en)	2016-03-04	2017-09-08	Rhode Island Hospital	Targeting microrna for cancer treatment
AU2017229778A1 (en)	2016-03-09	2018-08-16	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting PMP22 expression
WO2017158422A1 (en)	2016-03-16	2017-09-21	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
US10577607B2 (en)	2016-03-16	2020-03-03	Ionis Pharmaceuticals, Inc.	Modulation of DYRK1B expression
AU2017234678A1 (en)	2016-03-16	2018-08-16	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
CN109715802A (zh)	2016-03-18	2019-05-03	卡里斯科学公司	寡核苷酸探针及其用途
ES2933435T3 (es)	2016-04-13	2023-02-08	Ionis Pharmaceuticals Inc	Métodos para reducir la expresión de C9ORF72
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US20200330609A1 (en)	2016-04-18	2020-10-22	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CN109475568A (zh)	2016-05-06	2019-03-15	Ionis制药公司	Glp-1受体配体部分缀合的寡核苷酸及其用途
CA3024129A1 (en)	2016-05-16	2017-11-23	The Board Of Regents Of The University Of Texas System	Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3025486A1 (en)	2016-05-25	2017-11-30	Caris Science, Inc.	Oligonucleotide probes and uses thereof
EP3469083A1 (de)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
ES2929381T3 (es)	2016-06-15	2022-11-28	Streck Inc	Ensayos y métodos para determinar la resistencia microbiana
WO2017219017A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
EP4163293A1 (de)	2016-06-24	2023-04-12	The Scripps Research Institute	Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
WO2018002762A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
EP3478829A1 (de)	2016-06-29	2019-05-08	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von myotoner dystrophie typ 1 (dm1) und anderen erkrankungen
CA3029119A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
DK3481856T3 (da)	2016-07-06	2025-11-10	Vertex Pharma	Materialer og metoder til behandling af smerterelaterede lidelser
AU2017292173B2 (en)	2016-07-06	2022-01-13	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
EP3481430A4 (de)	2016-07-11	2020-04-01	Translate Bio Ma, Inc.	Nukleinsäurekonjugate und verwendungen davon
PL3484524T3 (pl)	2016-07-15	2023-03-20	Ionis Pharmaceuticals, Inc.	Związki i sposoby modulacji smn2
WO2018017754A1 (en)	2016-07-19	2018-01-25	Duke University	Therapeutic applications of cpf1-based genome editing
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JOP20190015A1 (ar)	2016-08-04	2019-02-04	Arrowhead Pharmaceuticals Inc	عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
AU2017312116A1 (en)	2016-08-17	2019-03-07	Solstice Biologics, Ltd.	Polynucleotide constructs
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
SG10201607303YA (en)	2016-09-01	2018-04-27	Agency Science Tech & Res	Antisense oligonucleotides to induce exon skipping
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
WO2018064593A1 (en)	2016-09-29	2018-04-05	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing tau expression
EP3522898A4 (de)	2016-10-06	2020-05-27	Ionis Pharmaceuticals, Inc.	Verfahren zum konjugieren von oligomeren verbindungen
SG10201609048RA (en)	2016-10-28	2018-05-30	Agency Science Tech & Res	Antisense oligonucleotides
EP3532638A4 (de)	2016-10-31	2020-07-29	University of Massachusetts	Targeting von microrna-101-3p in der krebstherapie
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
TWI788312B (zh)	2016-11-23	2023-01-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
JP7206214B2 (ja)	2016-12-13	2023-01-17	シアトルチルドレンズホスピタル（ディービーエイシアトルチルドレンズリサーチインスティテュート）	インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
WO2018112320A1 (en)	2016-12-16	2018-06-21	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
AU2018208505B2 (en)	2017-01-10	2024-03-07	Arrowhead Pharmaceuticals, Inc.	Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
JP7458785B2 (ja)	2017-01-23	2024-04-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	ヒドロキシステロイド１７－βデヒドロゲナーゼ１３（ＨＳＤ１７Ｂ１３）バリアント及びその使用
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
WO2018154462A2 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3585898A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von spinozerebellärer ataxie typ 1 (sca1) und anderen mit dem gen des proteins von spinozerebellärer ataxie typ 1 (atxn1) assoziierten erkrankungen oder störungen
EP3585895A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
US20180284123A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
EP3609521A4 (de)	2017-04-14	2021-06-16	University of Massachusetts	Targeting von zelltropismus-rezeptoren zur hemmung von infektionen durch das cytomegalovirus
EP3610022A1 (de)	2017-04-14	2020-02-19	Tollnine, Inc.	Immunmodulierende polynukleotide, antikörperkonjugate davon und verfahren zu deren verwendung
CN118384268A (zh)	2017-04-18	2024-07-26	阿尔尼拉姆医药品有限公司	具有乙肝病毒（hbv）感染的受试者的治疗方法
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
CA3059321A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
US11433131B2 (en)	2017-05-11	2022-09-06	Northwestern University	Adoptive cell therapy using spherical nucleic acids (SNAs)
CA3062506A1 (en)	2017-05-12	2019-05-23	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
US11597744B2 (en)	2017-06-30	2023-03-07	Sirius Therapeutics, Inc.	Chiral phosphoramidite auxiliaries and methods of their use
CN111093771A (zh)	2017-07-10	2020-05-01	建新公司	在患有血友病的受试者中治疗出血事件的方法和组合物
CA3069321A1 (en)	2017-07-11	2019-01-17	The Scripps Research Institute	Incorporation of unnatural nucleotides and methods thereof
EP3652186A4 (de)	2017-07-13	2021-03-31	Northwestern University	Allgemeines und direktes verfahren zur herstellung von oligonukleotidfunktionalisierten metallorganischen gerüstnanopartikeln
EP3652317A1 (de)	2017-07-13	2020-05-20	Alnylam Pharmaceuticals, Inc.	Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
KR20250145137A (ko)	2017-08-03	2025-10-13	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
EP3668984A4 (de)	2017-08-18	2021-09-08	Ionis Pharmaceuticals, Inc.	Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
US11806360B2 (en)	2017-09-19	2023-11-07	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
SG11202003464VA (en)	2017-10-17	2020-05-28	Crispr Therapeutics Ag	Compositions and methods for gene editing for hemophilia a
EP3701029A1 (de)	2017-10-26	2020-09-02	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
SG11202002940QA (en)	2017-11-01	2020-04-29	Alnylam Pharmaceuticals Inc	Complement component c3 irna compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
MA50579A (fr)	2017-11-09	2020-09-16	Crispr Therapeutics Ag	Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
EP3710587A1 (de)	2017-11-16	2020-09-23	Alnylam Pharmaceuticals, Inc.	Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
US10662425B2 (en)	2017-11-21	2020-05-26	Crispr Therapeutics Ag	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
JP2021505587A (ja)	2017-12-05	2021-02-18	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｃｒｉｓｐｒ−ｃａｓ９改変ｃｄ３４＋ヒト造血幹・前駆細胞及びその使用
WO2019118935A1 (en)	2017-12-14	2019-06-20	Casebia Therapeutics Limited Liability Partnership	Novel rna-programmable endonuclease systems and their use in genome editing and other applications
WO2019118916A1 (en)	2017-12-14	2019-06-20	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
JP2021508491A (ja)	2017-12-18	2021-03-11	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
WO2019123430A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3728594A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms typ 2a
US11459564B2 (en)	2017-12-21	2022-10-04	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
CN112105627B (zh)	2017-12-29	2024-07-02	斯克利普斯研究所	非天然碱基对组合物及使用方法
WO2019140102A1 (en)	2018-01-10	2019-07-18	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
US12215320B2 (en)	2018-01-12	2025-02-04	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting transferrin
PE20211242A1 (es)	2018-01-15	2021-07-09	Ionis Pharmaceuticals Inc	Moduladores de la expresion dnm2
JP7652567B2 (ja)	2018-01-19	2025-03-27	シンセナアーゲー	トリシクロ－ｄｎａヌクレオシド前駆体およびそれを調製するためのプロセス
EP3740580A4 (de)	2018-01-19	2021-10-20	Duke University	Genom-engineering mit crispr-cas-systemen bei eukaryonten
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
US11268077B2 (en)	2018-02-05	2022-03-08	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
EP3749767A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
WO2019157531A1 (en)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
EP3752616A1 (de)	2018-02-16	2020-12-23	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
EP4516358A3 (de)	2018-02-26	2025-04-23	Synthorx, Inc.	Il-15-konjugate und verwendungen davon
WO2019169243A1 (en)	2018-03-02	2019-09-06	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-beta precursor protein
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
CA3092497A1 (en)	2018-03-19	2019-09-26	Crispr Therapeutics Ag	Novel rna-programmable endonuclease systems and uses thereof
EP3768694A4 (de)	2018-03-22	2021-12-29	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der fmr1-expression
WO2019191429A2 (en)	2018-03-28	2019-10-03	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in dna isolated from exosomes
CA3095545A1 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
WO2019195738A1 (en)	2018-04-06	2019-10-10	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
PE20201349A1 (es)	2018-04-11	2020-11-30	Ionis Pharmaceuticals Inc	Moduladores de la expresion de ezh2
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
WO2019210057A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
EP3788065B1 (de)	2018-04-30	2025-08-27	The Children's Hospital Of Philadelphia	Verbesserung von anämien durch kombination von wirkstoffen
WO2019213571A1 (en)	2018-05-03	2019-11-07	The Trustees Of Wheaton College	Improved membranes for nanopore sensing applications
CR20200605A (es)	2018-05-09	2021-01-29	Ionis Pharmaceuticals Inc	Compuestos y métodos para la reducción de la expresión de fxi
CN112189053B (zh)	2018-05-09	2024-05-14	Ionis制药公司	用于减少atxn3表达的化合物和方法
US12582702B2 (en)	2018-05-11	2026-03-24	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
CA3103429A1 (en)	2018-06-14	2019-12-19	Don W. Cleveland	Compounds and methods for increasing stmn2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020018558A1 (en)	2018-07-17	2020-01-23	Aronora, Inc.	Methods for safely reducing thrombopoietin
NZ771733A (en)	2018-07-25	2025-10-31	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn2 expression
KR102918289B1 (ko)	2018-08-13	2026-01-28	알닐람 파마슈티칼스 인코포레이티드	B형 간염 바이러스 (HBV) dsRNA 제제 조성물 및 이의 사용 방법
EP3837367A1 (de)	2018-08-16	2021-06-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
EA202190581A1 (ru)	2018-08-20	2021-07-13	Рогкон, Инк.	Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
EP3843845B1 (de)	2018-08-29	2026-03-11	University Of Massachusetts	Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
SG11202102531WA (en)	2018-09-14	2021-04-29	Univ Northwestern	Programming protein polymerization with dna
CN118667811A (zh)	2018-09-18	2024-09-20	阿尔尼拉姆医药品有限公司	己酮糖激酶(KHK)iRNA组合物及其使用方法
TWI856973B (zh)	2018-09-19	2024-10-01	美商Ionis製藥公司	Pnpla3表現之調節劑
ES2966013T3 (es)	2018-09-25	2024-04-17	Co Diagnostics Inc	Diseño específico de alelo de cebadores cooperativos para genotipado de variantes de ácido nucleico mejorado
MX2021004455A (es)	2018-10-17	2021-08-11	Crispr Therapeutics Ag	Composiciones y métodos para administrar transgenes.
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
MX2021005293A (es)	2018-11-08	2021-06-23	Synthorx Inc	Conjugados de interleuquina 10 y usos de los mismos.
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EP3880821A4 (de)	2018-11-15	2023-01-25	Ionis Pharmaceuticals, Inc.	Modulatoren der irf5-expression
BR112021007476A2 (pt)	2018-11-21	2021-11-03	Ionis Pharmaceuticals Inc	Compostos e métodos para reduzir a expressão de príon
JP7564102B2 (ja)	2018-11-28	2024-10-08	クリスパーセラピューティクスアクチェンゲゼルシャフト	ＬＮＰでの使用に最適化された、ＣＡＳ９をコードするｍＲＮＡ
US12485136B2 (en)	2018-12-03	2025-12-02	Takeda Pharmaceuticals U.S.A., Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity
US20210332495A1 (en)	2018-12-06	2021-10-28	Northwestern University	Protein Crystal Engineering Through DNA Hybridization Interactions
PL4285929T3 (pl)	2018-12-20	2026-03-23	Humabs Biomed Sa	Terapia skojarzona hbv
CN113631709A (zh)	2018-12-20	2021-11-09	普拉克西斯精密药物股份有限公司	用于治疗kcnt1相关病症的组合物和方法
KR20210117271A (ko)	2018-12-21	2021-09-28	노쓰웨스턴유니버시티	근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
JP7394137B2 (ja)	2018-12-21	2023-12-07	アイオニス・ファーマシューティカルズ・インコーポレイテッド	Ｈｓｄ１７ｂ１３発現のモジュレータ
US20220062299A1 (en)	2018-12-26	2022-03-03	Northwestern University	Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
EP3911335A1 (de)	2019-01-16	2021-11-24	Genzyme Corporation	Serpinc1-irna-zusammensetzungen und verfahren zur verwendung davon
TW202214854A (zh)	2019-01-31	2022-04-16	美商Ionis製藥公司	Yap1表現之調節劑
SG11202107354WA (en)	2019-02-06	2021-08-30	Synthorx Inc	Il-2 conjugates and methods of use thereof
CA3129532A1 (en)	2019-02-15	2020-08-20	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
WO2020176771A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
US20220175956A1 (en)	2019-03-06	2022-06-09	Northwestern University	Hairpin-like oligonucleotide-conjugated spherical nucleic acid
US12486536B2 (en)	2019-03-11	2025-12-02	Ochsner Health System	MicroRNA regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
EP3937963B1 (de)	2019-03-12	2025-05-07	CRISPR Therapeutics AG	Neuartige rna-programmierbare high-fidelity-endonukleasesysteme und verwendungen davon
PL3947684T3 (pl)	2019-03-29	2025-07-21	Ionis Pharmaceuticals, Inc.	Związki i sposoby modulacji ube3a-ats
CA3139325A1 (en)	2019-05-13	2020-11-19	Vir Biotechnology, Inc.	Compositions and methods for treating hepatitis b virus (hbv) infection
LT3976791T (lt)	2019-05-28	2025-07-25	Ionis Pharmaceuticals, Inc.	Junginiai ir būdai fus raiškai mažinti
CA3140112A1 (en)	2019-05-31	2020-12-03	Streck, Inc.	Detection of antibiotic resistance genes
WO2020247774A1 (en)	2019-06-06	2020-12-10	Arrowhead Pharmaceuticals, Inc.	Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
TWI874408B (zh)	2019-06-14	2025-03-01	美商史基普研究協會	於半合成生物體中複製、轉錄及轉譯之試劑及方法
EP3956450B1 (de)	2019-07-26	2025-08-13	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation von gfap
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TWI873169B (zh)	2019-08-15	2025-02-21	美商欣爍克斯公司	使用il-2接合物之免疫腫瘤學組合療法
CN114555621B (zh)	2019-08-15	2025-10-28	Ionis制药公司	键修饰的寡聚化合物及其用途
BR112022003046A8 (pt)	2019-08-23	2024-02-06	Synthorx Inc	Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
CN114616331B (zh)	2019-09-03	2024-10-22	阿尔尼拉姆医药品有限公司	抑制lect2基因表达的组合物和方法
US12234271B2 (en)	2019-09-10	2025-02-25	Synthorx, Inc.	Il-2 conjugates and methods of use to treat autoimmune diseases
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
CN114728017B (zh)	2019-10-14	2025-10-28	阿斯利康(瑞典)有限公司	Pnpla3表达的调节剂
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
JP7676377B2 (ja)	2019-10-22	2025-05-14	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分Ｃ３ｉＲＮＡ組成物およびその使用方法
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
US20240168004A1 (en)	2019-10-31	2024-05-23	The Trustees Of Wheaton College	Design and characterization of multilayered structures for support of lipid bilayers
CN119499394A (zh)	2019-11-01	2025-02-25	阿尔尼拉姆医药品有限公司	亨廷顿（HTT）iRNA药剂组合物及其使用方法
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
EP4054644A1 (de)	2019-11-04	2022-09-14	Synthorx, Inc.	Interleukin-10-konjugate und deren verwendungen
WO2021096763A1 (en)	2019-11-13	2021-05-20	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
CA3159501A1 (en)	2019-11-27	2021-06-03	Brian Joseph CAFFERTY	Methods of synthesizing rna molecules
CA3164599A1 (en)	2019-12-13	2021-06-17	Alnylam Pharmaceuticals, Inc.	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
US20230054569A1 (en)	2019-12-18	2023-02-23	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
WO2021142245A1 (en)	2020-01-10	2021-07-15	Translate Bio, Inc.	Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
US12503695B2 (en)	2020-01-27	2025-12-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
KR20220143106A (ko)	2020-02-18	2022-10-24	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
AR121446A1 (es)	2020-02-28	2022-06-08	Ionis Pharmaceuticals Inc	Compuestos y métodos para modular smn2
WO2021174091A1 (en)	2020-02-28	2021-09-02	Tallac Therapeutics, Inc.	Transglutaminase-mediated conjugation
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022017822A2 (pt)	2020-03-06	2022-11-08	Alnylam Pharmaceuticals Inc	Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
CN116209759A (zh)	2020-03-26	2023-06-02	阿尔尼拉姆医药品有限公司	冠状病毒iRNA组合物及其使用方法
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
US12534731B2 (en)	2020-04-01	2026-01-27	Alnylam Pharmaceuticals, Inc.	Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
MX2022012493A (es)	2020-04-06	2022-10-27	Alnylam Pharmaceuticals Inc	Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
AU2021251754A1 (en)	2020-04-07	2022-11-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing SCN9A expression
JP2023522961A (ja)	2020-04-21	2023-06-01	フラッグシップパイオニアリング，インコーポレイテッド	二機能性分子およびその使用方法
AU2021263554A1 (en)	2020-04-27	2022-12-08	Alnylam Pharmaceuticals, Inc.	Apolipoprotein E (APOE) iRNA agent compositions and methods of use thereof
KR20230017789A (ko)	2020-04-30	2023-02-06	알닐람 파마슈티칼스 인코포레이티드	보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
AU2021264010A1 (en)	2020-05-01	2022-12-08	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating ATXN1
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150086A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
EP4150076A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
WO2021237097A1 (en)	2020-05-21	2021-11-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
WO2021252649A2 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
BR112022024420A2 (pt)	2020-06-18	2023-01-17	Alnylam Pharmaceuticals Inc	Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
US20230242621A1 (en)	2020-06-24	2023-08-03	Vir Biotechnology, Inc.	Engineered hepatitis b virus neutralizing antibodies and uses thereof
MX2022016254A (es)	2020-06-25	2023-04-11	Synthorx Inc	Terapia de combinación de inmunooncología con conjugados de il-2 y anticuerpos anti-egfr.
US11732263B2 (en)	2020-06-29	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating PLP1
JP2023536472A (ja)	2020-07-28	2023-08-25	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ａｐｐの発現を低減するための化合物及び方法
AU2021320384A1 (en)	2020-08-07	2023-02-16	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating SCN2A
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
US20230392134A1 (en)	2020-09-30	2023-12-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
EP4225917A1 (de)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2021357826A1 (en)	2020-10-09	2023-05-11	Board Of Regents, The University Of Texas System	Prefusion-stabilized hmpv f proteins
EP4225376A1 (de)	2020-10-09	2023-08-16	Synthorx, Inc.	Immunonkologische kombinationstherapie mit il-2-konjugaten und pembrolizumab
MX2023004032A (es)	2020-10-09	2023-04-27	Synthorx Inc	Terapias inmuno-oncologicas con conjugados de il-2.
WO2022087041A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
JP2023547615A (ja)	2020-10-23	2023-11-13	ザスクリプスリサーチインスティテュート	非天然ヌクレオチドを含むポリヌクレオチドの逆転写
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
EP4244355A1 (de)	2020-11-13	2023-09-20	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor-v (f5)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230108728A (ko)	2020-11-18	2023-07-18	아이오니스 파마수티컬즈, 인코포레이티드	앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
WO2022106695A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
US11987795B2 (en)	2020-11-24	2024-05-21	The Broad Institute, Inc.	Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
EP4256053A1 (de)	2020-12-01	2023-10-11	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
EP4259795A1 (de)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
TW202242111A (zh)	2020-12-18	2022-11-01	美商Ionis製藥公司	用於調節因子ｘｉｉ之化合物及方法
AU2021409740A1 (en)	2020-12-23	2023-07-06	Flagship Pioneering Innovations Vi, Llc	Compositions of modified trems and uses thereof
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
IL304880A (en)	2021-02-12	2023-10-01	Alnylam Pharmaceuticals Inc	Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
WO2022182574A1 (en)	2021-02-26	2022-09-01	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508896A (ja)	2021-03-04	2024-02-28	アルナイラムファーマシューティカルズ，インコーポレイテッド	アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
US20220288181A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
BR112023019981A2 (pt)	2021-03-29	2023-12-12	Alnylam Pharmaceuticals Inc	Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
US20250270575A1 (en)	2021-04-07	2025-08-28	Neoplants Sas	Compositions and methods for indoor air remediation
AU2022262422A1 (en)	2021-04-22	2023-11-02	The Board Of Regents Of The University Of Texas System	All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
TW202309280A (zh)	2021-04-26	2023-03-01	美商艾拉倫製藥股份有限公司	跨膜絲胺酸蛋白酶６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物及其使用方法
WO2022232343A1 (en)	2021-04-29	2022-11-03	Alnylam Pharmaceuticals, Inc.	Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4334448A1 (de)	2021-05-03	2024-03-13	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022246023A1 (en)	2021-05-20	2022-11-24	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
JP2024522996A (ja)	2021-06-02	2024-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
EP4346904A1 (de)	2021-06-03	2024-04-10	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und cetuximab
WO2022256290A2 (en)	2021-06-04	2022-12-08	Alnylam Pharmaceuticals, Inc.	HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
US20240141312A1 (en)	2021-06-11	2024-05-02	Bayer Aktiengesellschaft	Type v rna programmable endonuclease systems
CA3223192A1 (en)	2021-06-18	2022-12-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ifnar1 expression
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
JP2024527304A (ja)	2021-06-30	2024-07-24	アルナイラムファーマシューティカルズ，インコーポレイテッド	アンジオテンシノーゲン（ａｇｔ）関連障害を治療するための方法および組成物
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
WO2023003995A1 (en)	2021-07-23	2023-01-26	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
IL310244A (en)	2021-08-03	2024-03-01	Alnylam Pharmaceuticals Inc	Transthyretin (TTR) IRNA compositions and methods of using them
MX2024001445A (es)	2021-08-04	2024-02-27	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) y metodos para silenciar el angiotensinogeno (agt).
JP2024534766A (ja)	2021-08-13	2024-09-26	アルナイラムファーマシューティカルズ，インコーポレイテッド	第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
AU2022339821A1 (en)	2021-08-31	2024-03-07	Alnylam Pharmaceuticals, Inc.	Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
US11833221B2 (en)	2021-09-01	2023-12-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds for reducing DMPK expression
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
AU2022345881A1 (en)	2021-09-20	2024-03-21	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
CA3233097A1 (en)	2021-09-30	2023-04-06	Katherine Diane GRIBBLE	Compositions and methods for treating kcnq4-associated hearing loss
MX2024004011A (es)	2021-10-01	2024-07-01	Adarx Pharmaceuticals Inc	Composiciones moduladoras de precalicreína y métodos de uso de estas.
CA3234835A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
JP2024541989A (ja)	2021-10-29	2024-11-13	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
EP4444881A2 (de)	2021-11-10	2024-10-16	University of Rochester	Auf gata4 abzielende therapeutika zur behandlung von herzhypertrophie
CA3237770A1 (en)	2021-11-10	2023-05-19	University Of Rochester	Antisense oligonucleotides for modifying protein expression
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
EP4452327A1 (de)	2021-12-20	2024-10-30	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
CA3243006A1 (en)	2021-12-21	2025-02-27	Alia Therapeutics Srl	TYPE II CAS PROTEINS AND THEIR APPLICATIONS
CA3243301A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
EP4486890A1 (de)	2022-03-01	2025-01-08	CRISPR Therapeutics AG	Verfahren und zusammensetzungen zur behandlung von angiopoietin-like 3 (angptl3)-bedingten erkrankungen
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
AU2023284048A1 (en)	2022-06-10	2024-11-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
US20260049314A1 (en)	2022-08-29	2026-02-19	University Of Rochester	Antisense oligonucleotide-based anti-fibrotic therapeutics
EP4569113A1 (de)	2022-09-15	2025-06-18	Regeneron Pharmaceuticals, Inc.	17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung
CA3267752A1 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS
CN120239607A (zh)	2022-09-23	2025-07-01	Ionis制药公司	用于降低mecp2表达的化合物和方法
EP4619535A1 (de)	2022-11-16	2025-09-24	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
AU2023398007A1 (en)	2022-12-13	2025-06-19	Bayer Aktiengesellschaft	Engineered type v rna programmable endonucleases and their uses
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
IL321992A (en)	2023-01-09	2025-09-01	Univ Texas	Human parainfluenza virus 3f proteins stabilized before transfusion
JP2026502531A (ja)	2023-01-11	2026-01-23	アリアセラピューティクスエスアールエル	Ｉｉ型ｃａｓタンパク質およびその適用
TW202449152A (zh)	2023-02-09	2024-12-16	美商艾拉倫製藥股份有限公司	Ｒｅｖｅｒｓｉｒ分子及其使用方法
WO2024170778A1 (en)	2023-02-17	2024-08-22	Anjarium Biosciences Ag	Methods of making dna molecules and compositions and uses thereof
WO2024196937A1 (en)	2023-03-20	2024-09-26	Synthorx, Inc.	Cancer therapy with il-2 peg conjugates
WO2024197242A1 (en)	2023-03-23	2024-09-26	Carbon Biosciences, Inc.	Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
WO2024196965A1 (en)	2023-03-23	2024-09-26	Carbon Biosciences, Inc.	Parvovirus compositions and related methods for gene therapy
EP4678646A1 (de)	2023-04-06	2026-01-14	Shanghai Argo Biopharmaceutical Co., Ltd.	Nukleosidanalog zur 5'-phosphonatmodifizierung und daraus hergestelltes oligonukleotid
KR20260007584A (ko)	2023-04-20	2026-01-14	아다르엑스 파마슈티컬스, 인크.	Mapt-조절 조성물 및 이의 사용 방법
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
EP4709422A1 (de)	2023-05-12	2026-03-18	Adarx Pharmaceuticals, Inc.	Nmda-ligand-konjugierte verbindungen und verwendungen davon
WO2024243062A1 (en)	2023-05-19	2024-11-28	Streck Llc	Detection of antibiotic resistance genes
WO2024249328A2 (en)	2023-05-26	2024-12-05	Adarx Pharmaceuticals, Inc.	Sod1-modulating compositions and methods of use thereof
KR20260026066A (ko)	2023-06-20	2026-02-25	아다르엑스 파마슈티컬스, 인크.	Lrrk2 조절 조성물 및 이의 사용 방법
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025024493A1 (en)	2023-07-25	2025-01-30	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
WO2025024486A2 (en)	2023-07-25	2025-01-30	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
CN121605192A (zh)	2023-08-04	2026-03-03	阿尔尼拉姆医药品有限公司	用于治疗ctnnb1-相关病症的方法和组合物
GB202314724D0 (en)	2023-09-26	2023-11-08	Astrazeneca Ab	compounds and methods for reducing psd3 expression
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025076291A1 (en)	2023-10-06	2025-04-10	Bluerock Therapeutics Lp	Engineered type v rna programmable endonucleases and their uses
AU2024369609A1 (en)	2023-10-31	2025-12-11	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
EP4665854A1 (de)	2024-01-29	2025-12-24	Arnatar Therapeutics, Inc	Translationsverstärkende nukleinsäureverbindungen: aso-gekoppelte translation - hochregulierung 1 (act-up1) und verwendungen davon
WO2025165891A1 (en)	2024-01-29	2025-08-07	Arnatar Therapeutics, Inc	Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
US20250263702A1 (en)	2024-02-19	2025-08-21	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en)	2024-03-26	2024-05-08	Senisca Ltd	Novel oligoncleotides
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870700A (en) *	1973-05-29	1975-03-11	Miles Lab	2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) *	1978-10-02	1980-07-08	Sloan Kettering Institute For Cancer Research	5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4711955A (en) *	1981-04-17	1987-12-08	Yale University	Modified nucleotides and methods of preparing and using same
GB8517402D0 (en) *	1985-07-10	1985-08-14	Wellcome Found	Treatment of viral infections
DE3606634A1 (de) *	1986-02-28	1987-09-03	Mack Chem Pharm	Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5047519A (en) *	1986-07-02	1991-09-10	E. I. Du Pont De Nemours And Company	Alkynylamino-nucleotides
GB8629892D0 (en) *	1986-12-15	1987-01-28	Wellcome Found	Antiviral compounds

1988
- 1988-06-24 AT AT88905594T patent/ATE113059T1/de not_active IP Right Cessation
- 1988-06-24 NZ NZ225176A patent/NZ225176A/xx unknown
- 1988-06-24 JP JP63505657A patent/JP2828642B2/ja not_active Expired - Lifetime
- 1988-06-24 CA CA000570427A patent/CA1340032C/en not_active Expired - Fee Related
- 1988-06-24 WO PCT/AU1988/000207 patent/WO1988010264A1/en not_active Ceased
- 1988-06-24 DE DE3851889T patent/DE3851889T2/de not_active Expired - Lifetime
- 1988-06-24 EP EP88905594A patent/EP0366685B1/de not_active Expired - Lifetime
- 1988-06-24 AU AU19909/88A patent/AU598946B2/en not_active Expired
1993
- 1993-05-27 US US08/068,604 patent/US5552540A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU1990988A (en)	1989-01-19
DE3851889T2 (de)	1995-04-13
US5552540A (en)	1996-09-03
CA1340032C (en)	1998-09-08
AU598946B2 (en)	1990-07-05
EP0366685B1 (de)	1994-10-19
NZ225176A (en)	1990-09-26
JP2828642B2 (ja)	1998-11-25
EP0366685A4 (en)	1991-03-20
EP0366685A1 (de)	1990-05-09
DE3851889D1 (de)	1994-11-24
WO1988010264A1 (en)	1988-12-29
JPH02504144A (ja)	1990-11-29

Legal Events

Date	Code	Title	Description
1995-04-15	UEP	Publication of translation of european patent specification
2008-09-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
ATE113059T1 (de)	1994-11-15	Nukleosid-derivate.
DK345285D0 (da)	1985-07-30	Diphosphonsyrederivater, fremgangsmaade til deres fremstilling og laegemidler, der indeholder disse forbindelser
ATE215078T1 (de)	2002-04-15	Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
ES2156994T3 (es)	2001-08-01	Sustratos para beta-lactamasa y usos de estos sustratos.
DE3854454D1 (de)	1995-10-19	Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung.
ES8800186A1 (es)	1987-10-16	Un metodo para preparar derivados de tiazol
ES8802363A1 (es)	1988-06-01	Procedimiento para la fabricacion de derivados nucleosidos
SE7706392L (sv)	1977-12-10	N-fosfonometylenmonoaminoalkanmono- och -polyfosfonsyror respektive n-fosfonometylendiaminoalkanpolyfosfonsyror samt sett for deras framstellning
EP0347930A3 (de)	1992-01-02	Metalloxid enthaltende Mischung
DE68910655D1 (de)	1993-12-16	Kesselsteinverhütung.
ES8706148A1 (es)	1987-06-01	Un procedimiento para preparar nuevos derivados de carbapenem.
DK341985A (da)	1986-01-28	Antihoste og slimregulerende 2-substituerede thiazolidiner
KR840005733A (ko)	1984-11-16	무라밀 펩타이드의 제조방법
CO4970706A1 (es)	2000-11-07	Procedimiento de preparacion de compuestos de [2,3-d] pirimidinas 5-sustituidos por derivados de acido hidroxamico e intermediarios de reaccion
CO4960660A1 (es)	2000-09-25	Derivados de 5-aroil-pirrol-2-ilmetilareno, composiciones farmaceuticas que las contienen y metodos para la preparacion de estos compuestos
EP0547231A4 (en)	1994-06-08	Phospholipase a 2? inhibitor
IL86952A (en)	1993-01-14	Synthesis of aminomethylene phosphonoalkylphos- phinates
ES8703433A1 (es)	1987-02-16	Un procedimiento para preparar un derivado triciclico de pi-ridazinona
TW328083B (en)	1998-03-11	New derivatives of β-methoxy acrylic acid, their preparation process and their use as pesticides
ES8200899A1 (es)	1981-11-16	Procedimiento para la preparacion de derivados de bis (4-ce-metoxidaunorubicin)dihidrazona
DK558786A (da)	1987-05-24	Basisk substituerede pyridinforbindelser, fremstilling deraf, samt laegemidler, indeholdende disse
ATE121465T1 (de)	1995-05-15	Verfahren zur korrosionsinhibierung.
PE25195A1 (es)	1995-09-29	Sintesis de l-aspartil-d-aminoalcanoil-(s)-o-alquilbencil amida utilizada como endulzante artificial
ATE154359T1 (de)	1997-06-15	2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung
ATE6500T1 (de)	1984-03-15	2-alpha-methyl-dopaminimino-6,7-dihydroxy-1,2,3 4-tetrahydronaphthalin, seine salze, und verfahren zu dessen herstellung.